1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Ghasriani, H. Belcourt, P.J.F. Sauve, S. Hodgson, D.J. Gingras, G. Brochu, D. Gilbert, M. Aubin, Y. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic C8 H15 N O6 221.208 2-acetamido-2-deoxy-alpha-D-galactopyranose N-acetyl-alpha-D-galactosamine; 2-acetamido-2-deoxy-alpha-D-galactose; 2-acetamido-2-deoxy-D-galactose; 2-acetamido-2-deoxy-galactose; N-ACETYL-2-DEOXY-2-AMINO-GALACTOSE D-saccharide, alpha linking C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US J.Biol.Chem. JBCHA3 0071 0021-9258 288 247 254 10.1074/jbc.M112.413252 23184955 A single N-acetylgalactosamine residue at threonine 106 modifies the dynamics and structure of interferon alpha2a around the glycosylation site. 2013 10.2210/pdb2lms/pdb pdb_00002lms 19395.291 Interferon alpha-2 1 man polymer 221.208 2-acetamido-2-deoxy-alpha-D-galactopyranose 1 man non-polymer IFN-alpha-2, Interferon alpha-A, LeIF A no no MCDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDET LLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQE SLRSKE MCDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDET LLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQE SLRSKE A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n human sample IFNA2 9606 Homo sapiens 469008 Escherichia coli BL21 DE3 pET-15b atom_site chem_comp entity pdbx_chem_comp_identifier pdbx_entity_nonpoly pdbx_nmr_spectrometer struct_conn struct_ref_seq_dif struct_site struct_site_gen chem_comp database_2 pdbx_database_status repository Initial release Carbohydrate remediation repository Remediation Database references Atomic model Data collection Database references Derived calculations Structure summary Database references Other Structure summary 1 0 2012-12-05 1 1 2013-05-01 2 0 2020-07-29 2 1 2023-06-14 _atom_site.auth_atom_id _atom_site.label_atom_id _chem_comp.name _chem_comp.type _entity.pdbx_description _pdbx_entity_nonpoly.name _pdbx_nmr_spectrometer.model _struct_conn.pdbx_leaving_atom_flag _struct_conn.pdbx_role _struct_ref_seq_dif.details _chem_comp.pdbx_synonyms _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_database_status.status_code_nmr_data DGalpNAca N-acetyl-a-D-galactopyranosamine a-D-GalpNAc GalNAc BMRB Y RCSB 2011-12-12 REL REL REL REL A2G 2-acetamido-2-deoxy-alpha-D-galactopyranose structures with the least restraint violations 100 20 3D HNCO 3D HNCA 3D HNCACB 3D CBCA(CO)NH 3D HBHA(CO)NH 3D HCCH-TOCSY 3D 1H-15N NOESY 3D 1H-13C NOESY aliphatic 3D 1H-13C NOESY aromatic 3D C(CO)NH 2D (hb)CB(cgcd)HD 2D (hb)CB(cgcdce)HE 4D (C13)HSQC-NOESY-(N15)HSQC 4D (C13)HSQC-NOESY-(C13)HSQC 0.85 mM [U-100% 13C; U-100% 15N] 0.53 mM [U-100% 13C; U-100% 15N] 0.87 mM [U-100% 13C; U-100% 15N] 25 3.5 ambient 298.15 K torsion angle dynamics 1 fewest violations 0.85 mM [U-100% 13C; U-100% 15N] Interferon Alpha-2a (O-glycosylated), 90% H2O/10% D2O 90% H2O/10% D2O 0.87 mM [U-100% 13C; U-100% 15N] Interferon Alpha-2a (O-glycosylated), 100% D2O 100% D2O Guntert, Mumenthaler and Wuthrich structure solution CYANA 2.1 Guntert, Mumenthaler and Wuthrich refinement CYANA 700 Bruker AVANCE Bruker Avance 600 Bruker AVANCE III Bruker Avance III A2G 500 2 A2G A2G 500 A n 1 0 A CYS 1 n 2 CYS 1 A ASP 2 n 3 ASP 2 A LEU 3 n 4 LEU 3 A PRO 4 n 5 PRO 4 A GLN 5 n 6 GLN 5 A THR 6 n 7 THR 6 A HIS 7 n 8 HIS 7 A SER 8 n 9 SER 8 A LEU 9 n 10 LEU 9 A GLY 10 n 11 GLY 10 A SER 11 n 12 SER 11 A ARG 12 n 13 ARG 12 A ARG 13 n 14 ARG 13 A THR 14 n 15 THR 14 A LEU 15 n 16 LEU 15 A MET 16 n 17 MET 16 A LEU 17 n 18 LEU 17 A LEU 18 n 19 LEU 18 A ALA 19 n 20 ALA 19 A GLN 20 n 21 GLN 20 A MET 21 n 22 MET 21 A ARG 22 n 23 ARG 22 A LYS 23 n 24 LYS 23 A ILE 24 n 25 ILE 24 A SER 25 n 26 SER 25 A LEU 26 n 27 LEU 26 A PHE 27 n 28 PHE 27 A SER 28 n 29 SER 28 A CYS 29 n 30 CYS 29 A LEU 30 n 31 LEU 30 A LYS 31 n 32 LYS 31 A ASP 32 n 33 ASP 32 A ARG 33 n 34 ARG 33 A HIS 34 n 35 HIS 34 A ASP 35 n 36 ASP 35 A PHE 36 n 37 PHE 36 A GLY 37 n 38 GLY 37 A PHE 38 n 39 PHE 38 A PRO 39 n 40 PRO 39 A GLN 40 n 41 GLN 40 A GLU 41 n 42 GLU 41 A GLU 42 n 43 GLU 42 A PHE 43 n 44 PHE 43 A GLY 44 n 45 GLY 44 A ASN 45 n 46 ASN 45 A GLN 46 n 47 GLN 46 A PHE 47 n 48 PHE 47 A GLN 48 n 49 GLN 48 A LYS 49 n 50 LYS 49 A ALA 50 n 51 ALA 50 A GLU 51 n 52 GLU 51 A THR 52 n 53 THR 52 A ILE 53 n 54 ILE 53 A PRO 54 n 55 PRO 54 A VAL 55 n 56 VAL 55 A LEU 56 n 57 LEU 56 A HIS 57 n 58 HIS 57 A GLU 58 n 59 GLU 58 A MET 59 n 60 MET 59 A ILE 60 n 61 ILE 60 A GLN 61 n 62 GLN 61 A GLN 62 n 63 GLN 62 A ILE 63 n 64 ILE 63 A PHE 64 n 65 PHE 64 A ASN 65 n 66 ASN 65 A LEU 66 n 67 LEU 66 A PHE 67 n 68 PHE 67 A SER 68 n 69 SER 68 A THR 69 n 70 THR 69 A LYS 70 n 71 LYS 70 A ASP 71 n 72 ASP 71 A SER 72 n 73 SER 72 A SER 73 n 74 SER 73 A ALA 74 n 75 ALA 74 A ALA 75 n 76 ALA 75 A TRP 76 n 77 TRP 76 A ASP 77 n 78 ASP 77 A GLU 78 n 79 GLU 78 A THR 79 n 80 THR 79 A LEU 80 n 81 LEU 80 A LEU 81 n 82 LEU 81 A ASP 82 n 83 ASP 82 A LYS 83 n 84 LYS 83 A PHE 84 n 85 PHE 84 A TYR 85 n 86 TYR 85 A THR 86 n 87 THR 86 A GLU 87 n 88 GLU 87 A LEU 88 n 89 LEU 88 A TYR 89 n 90 TYR 89 A GLN 90 n 91 GLN 90 A GLN 91 n 92 GLN 91 A LEU 92 n 93 LEU 92 A ASN 93 n 94 ASN 93 A ASP 94 n 95 ASP 94 A LEU 95 n 96 LEU 95 A GLU 96 n 97 GLU 96 A ALA 97 n 98 ALA 97 A CYS 98 n 99 CYS 98 A VAL 99 n 100 VAL 99 A ILE 100 n 101 ILE 100 A GLN 101 n 102 GLN 101 A GLY 102 n 103 GLY 102 A VAL 103 n 104 VAL 103 A GLY 104 n 105 GLY 104 A VAL 105 n 106 VAL 105 A THR 106 n 107 THR 106 A GLU 107 n 108 GLU 107 A THR 108 n 109 THR 108 A PRO 109 n 110 PRO 109 A LEU 110 n 111 LEU 110 A MET 111 n 112 MET 111 A LYS 112 n 113 LYS 112 A GLU 113 n 114 GLU 113 A ASP 114 n 115 ASP 114 A SER 115 n 116 SER 115 A ILE 116 n 117 ILE 116 A LEU 117 n 118 LEU 117 A ALA 118 n 119 ALA 118 A VAL 119 n 120 VAL 119 A ARG 120 n 121 ARG 120 A LYS 121 n 122 LYS 121 A TYR 122 n 123 TYR 122 A PHE 123 n 124 PHE 123 A GLN 124 n 125 GLN 124 A ARG 125 n 126 ARG 125 A ILE 126 n 127 ILE 126 A THR 127 n 128 THR 127 A LEU 128 n 129 LEU 128 A TYR 129 n 130 TYR 129 A LEU 130 n 131 LEU 130 A LYS 131 n 132 LYS 131 A GLU 132 n 133 GLU 132 A LYS 133 n 134 LYS 133 A LYS 134 n 135 LYS 134 A TYR 135 n 136 TYR 135 A SER 136 n 137 SER 136 A PRO 137 n 138 PRO 137 A CYS 138 n 139 CYS 138 A ALA 139 n 140 ALA 139 A TRP 140 n 141 TRP 140 A GLU 141 n 142 GLU 141 A VAL 142 n 143 VAL 142 A VAL 143 n 144 VAL 143 A ARG 144 n 145 ARG 144 A ALA 145 n 146 ALA 145 A GLU 146 n 147 GLU 146 A ILE 147 n 148 ILE 147 A MET 148 n 149 MET 148 A ARG 149 n 150 ARG 149 A SER 150 n 151 SER 150 A PHE 151 n 152 PHE 151 A SER 152 n 153 SER 152 A LEU 153 n 154 LEU 153 A SER 154 n 155 SER 154 A THR 155 n 156 THR 155 A ASN 156 n 157 ASN 156 A LEU 157 n 158 LEU 157 A GLN 158 n 159 GLN 158 A GLU 159 n 160 GLU 159 A SER 160 n 161 SER 160 A LEU 161 n 162 LEU 161 A ARG 162 n 163 ARG 162 A SER 163 n 164 SER 163 A LYS 164 n 165 LYS 164 A GLU 165 n 166 GLU 165 A author_defined_assembly 1 monomeric A THR 106 GLYCOSYLATION SITE A THR 107 THR 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 1 A MET 0 A MET 1 1 Y 2 A MET 0 A MET 1 1 Y 3 A MET 0 A MET 1 1 Y 4 A MET 0 A MET 1 1 Y 5 A MET 0 A MET 1 1 Y 6 A MET 0 A MET 1 1 Y 7 A MET 0 A MET 1 1 Y 8 A MET 0 A MET 1 1 Y 9 A MET 0 A MET 1 1 Y 10 A MET 0 A MET 1 1 Y 11 A MET 0 A MET 1 1 Y 12 A MET 0 A MET 1 1 Y 13 A MET 0 A MET 1 1 Y 14 A MET 0 A MET 1 1 Y 15 A MET 0 A MET 1 1 Y 16 A MET 0 A MET 1 1 Y 17 A MET 0 A MET 1 1 Y 18 A MET 0 A MET 1 1 Y 19 A MET 0 A MET 1 1 Y 20 A MET 0 A MET 1 1 Y 1 A PRO 4 -69.83 68.12 1 A CYS 29 -155.93 88.97 1 A ASP 32 -130.31 -31.51 1 A ASP 35 178.85 166.24 1 A PRO 39 -69.79 81.17 1 A ASN 45 -155.83 73.05 1 A PHE 84 -63.22 -74.62 1 A SER 163 -52.05 103.60 2 A LEU 3 -46.97 156.04 2 A PRO 4 -69.74 65.92 2 A CYS 29 -157.43 85.50 2 A HIS 34 62.07 81.24 2 A ASP 35 -132.08 -43.17 2 A PRO 39 -69.79 81.30 2 A PHE 84 -62.41 -72.61 3 A LEU 3 -48.74 156.66 3 A PRO 4 -69.80 64.05 3 A CYS 29 -159.18 84.10 3 A HIS 34 60.39 100.24 3 A ASP 35 -151.88 -41.44 3 A PRO 39 -69.79 83.72 3 A ASN 45 -149.82 59.35 3 A PHE 84 -62.93 -72.28 3 A ASN 156 -100.20 63.63 3 A LEU 161 -73.48 -74.98 4 A LEU 3 -47.92 156.92 4 A PRO 4 -69.81 68.57 4 A CYS 29 -155.29 88.59 4 A HIS 34 51.52 89.22 4 A ASP 35 -139.26 -56.27 4 A PRO 39 -69.80 81.85 4 A PHE 84 -60.25 -72.05 4 A SER 136 -49.72 168.41 5 A LEU 3 -47.93 157.13 5 A PRO 4 -69.76 76.06 5 A CYS 29 -153.67 89.39 5 A ASP 35 -166.91 -50.80 5 A PRO 39 -69.72 75.29 5 A ASN 45 -151.46 53.93 5 A PHE 84 -62.75 -72.13 5 A SER 160 -151.47 25.93 5 A LEU 161 -92.36 -75.37 6 A LEU 3 -47.15 158.73 6 A PRO 4 -69.81 65.29 6 A CYS 29 -152.35 88.56 6 A HIS 34 58.89 95.06 6 A ASP 35 -148.74 -50.65 6 A PRO 39 -69.80 81.95 6 A PHE 84 -59.47 -71.66 6 A LYS 164 -98.58 39.16 7 A LEU 3 -49.08 158.32 7 A PRO 4 -69.80 64.70 7 A CYS 29 -162.31 88.39 7 A HIS 34 58.72 98.01 7 A ASP 35 -159.34 -42.27 7 A PRO 39 -69.81 77.34 7 A GLN 46 -95.57 34.08 7 A PHE 84 -58.21 -71.98 7 A ASN 156 -103.16 58.81 7 A LEU 161 -68.04 -74.93 8 A LEU 3 -48.26 158.43 8 A PRO 4 -69.79 69.69 8 A CYS 29 -159.35 86.56 8 A HIS 34 51.37 84.20 8 A ASP 35 -138.39 -42.21 8 A PRO 39 -69.77 91.38 8 A ASN 45 -154.89 61.72 8 A PHE 84 -58.77 -71.57 8 A SER 136 -49.81 168.75 8 A ASN 156 -90.16 59.89 8 A LEU 161 -89.77 -74.90 9 A LEU 3 -48.29 158.26 9 A PRO 4 -69.83 70.01 9 A CYS 29 -152.95 87.60 9 A ASP 35 -170.01 -40.23 9 A PHE 36 -52.08 -71.57 9 A PRO 39 -69.75 86.79 9 A GLN 46 -94.57 39.02 9 A PHE 84 -63.67 -72.50 9 A GLN 101 -59.56 175.28 9 A SER 160 -178.87 86.27 10 A LEU 3 -48.02 158.92 10 A PRO 4 -69.78 65.37 10 A CYS 29 -154.38 88.02 10 A ASP 35 -159.01 -52.65 10 A PRO 39 -69.71 80.92 10 A PHE 84 -61.30 -72.00 10 A GLU 159 -179.65 -173.89 11 A ASP 2 -112.57 66.78 11 A PRO 4 -69.76 62.90 11 A CYS 29 -155.24 88.62 11 A ASP 35 -162.38 -44.30 11 A PRO 39 -69.71 81.91 11 A ASN 45 -159.01 76.56 11 A PHE 84 -61.88 -72.09 11 A SER 160 -159.45 30.42 11 A LEU 161 -89.46 -75.53 11 A ARG 162 -97.99 -66.82 12 A LEU 3 -47.89 159.43 12 A PRO 4 -69.73 69.50 12 A ASP 35 -157.07 -41.37 12 A PRO 39 -69.85 78.96 12 A PHE 84 -60.16 -72.06 12 A SER 160 -149.20 24.69 13 A LEU 3 -48.24 158.98 13 A PRO 4 -69.72 74.20 13 A CYS 29 -157.38 83.58 13 A HIS 34 59.36 99.62 13 A ASP 35 -151.54 -41.45 13 A PRO 39 -69.80 85.37 13 A ASN 45 -159.25 56.63 13 A PHE 84 -60.10 -71.87 13 A LEU 161 -68.83 -176.40 14 A LEU 3 -48.80 156.85 14 A PRO 4 -69.76 65.84 14 A CYS 29 -151.53 87.48 14 A ASP 35 -121.72 -58.36 14 A PRO 39 -69.80 82.15 14 A ASN 45 -155.79 42.08 14 A PHE 84 -61.59 -72.11 15 A LEU 3 -48.45 150.45 15 A PRO 4 -69.78 85.65 15 A CYS 29 -152.35 88.14 15 A ASP 35 -159.30 -41.77 15 A PRO 39 -69.81 88.85 15 A ASN 45 -144.76 44.28 15 A PHE 84 -59.07 -71.54 15 A ASN 156 -104.24 56.46 15 A LEU 161 -105.32 -71.36 16 A PRO 4 -69.80 62.69 16 A PHE 36 -92.37 40.80 16 A PRO 39 -69.79 80.86 16 A GLN 46 -91.69 40.04 16 A PHE 84 -62.02 -71.14 16 A SER 136 -49.91 168.34 16 A SER 160 -61.98 93.80 16 A LEU 161 -145.82 -67.78 17 A LEU 3 -47.61 155.86 17 A PRO 4 -69.72 67.99 17 A CYS 29 -154.79 89.00 17 A ASP 35 -146.78 -45.61 17 A PRO 39 -69.81 78.18 17 A ASN 45 -160.00 45.22 17 A PHE 84 -61.56 -71.78 17 A SER 136 -49.78 168.92 17 A LEU 161 -71.74 -168.69 17 A LYS 164 -72.43 -71.62 18 A LEU 3 -47.28 160.73 18 A PRO 4 -69.80 69.72 18 A CYS 29 -158.01 88.26 18 A HIS 34 59.09 100.73 18 A ASP 35 -153.37 -41.28 18 A PRO 39 -69.80 78.25 18 A PHE 84 -58.83 -71.75 18 A VAL 105 -175.84 136.64 18 A LYS 164 -95.82 36.86 19 A LEU 3 -49.54 158.74 19 A PRO 4 -69.72 78.00 19 A CYS 29 -151.82 87.54 19 A ASP 35 -176.31 -35.83 19 A PHE 36 -53.73 -72.25 19 A PRO 39 -69.75 89.29 19 A PHE 84 -59.99 -72.46 19 A ASN 156 -89.57 48.60 19 A LYS 164 -74.93 -72.20 20 A LEU 3 -47.26 155.47 20 A PRO 4 -69.72 70.77 20 A CYS 29 -151.60 87.49 20 A ASP 35 -160.83 -40.39 20 A PRO 39 -69.78 84.96 20 A ASN 45 -151.17 37.26 20 A GLN 46 -93.60 39.16 20 A PHE 84 -61.61 -71.91 20 A ASN 156 -101.35 61.02 20 A SER 160 -146.99 30.24 20 A LEU 161 -89.34 -75.18 fewest violations, model 1 A single GalNAc residue on Threonine-106 modifies the dynamics and the structure of Interferon alpha-2a around the glycosylation site 1 N N 2 N N A LEU 9 A LEU 10 HELX_P A ARG 22 A ARG 23 1 1 14 A SER 25 A SER 26 HELX_P A CYS 29 A CYS 30 5 2 5 A PRO 39 A PRO 40 HELX_P A GLY 44 A GLY 45 1 3 6 A GLU 51 A GLU 52 HELX_P A SER 68 A SER 69 1 4 18 A THR 69 A THR 70 HELX_P A TRP 76 A TRP 77 1 5 8 A ASP 77 A ASP 78 HELX_P A GLN 101 A GLN 102 1 6 25 A THR 108 A THR 109 HELX_P A LYS 133 A LYS 134 1 7 26 A CYS 138 A CYS 139 HELX_P A ASN 156 A ASN 157 1 8 19 disulf 2.141 A CYS 1 A SG CYS 2 1_555 A CYS 98 A SG CYS 99 1_555 disulf 1.946 A CYS 29 A SG CYS 30 1_555 A CYS 138 A SG CYS 139 1_555 covale 1.540 one O-Glycosylation A THR 106 A OG1 THR 107 1_555 A A2G 500 B C1 A2G 1_555 IMMUNE SYSTEM CYTOKINE, GLYCOPROTEIN, O-GLYCOSYLATION, SIGNALING PROTEIN, TYPE I INTERFERONS, IMMUNE SYSTEM IFNA2_HUMAN UNP 1 24 P01563 CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETL LDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQES LRSKE 24 188 2LMS 1 165 P01563 A 1 2 166 1 initiating methionine MET 0 2LMS A P01563 UNP 1